Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats  by Blasi, Eileen R. et al.
Kidney International, Vol. 63 (2003), pp. 1791–1800
Aldosterone/salt induces renal inflammation and fibrosis in
hypertensive rats
EILEEN R. BLASI, RICARDO ROCHA, AMY E. RUDOLPH, ERIC A.G. BLOMME, MELISSA L. POLLY,
and ELLEN G. MCMAHON
Pharmacia Corporation, Cardiovascular and Metabolic Diseases, Global Medical Affairs, and Global Toxicology,
St. Louis, Missouri, Peapack, New Jersey, and Skokie, Illinois
Aldosterone/salt induces renal inflammation and fibrosis in In the kidney, aldosterone mediates salt and water
hypertensive rats. homeostasis by binding to the mineralocorticoid recep-
Background. We evaluated the role of aldosterone as a me- tor (MR), which is expressed in renal epithelial cells.
diator of renal inflammation and fibrosis in a rat model of
However, the MR is also present in nonepithelial tissuesaldosterone/salt hypertension using the selective aldosterone
such as in vascular smooth muscle cells, cardiomyocytes,blocker, eplerenone.
neurons [1], and mononuclear leukocytes [2]. ActivationMethods. Unnephrectomized, Sprague-Dawley rats were
given 1% NaCl (salt) to drink and randomized to receive treat- of the MR by aldosterone contributes to kidney damage
ment for 28 days: vehicle infusion (control); 0.75 g/hour aldo- in experimental models of hypertension. Indeed, admin-
sterone subcutaneous infusion; or aldosterone infusion  100 istration of aldosterone blockers or aldosterone ablation
mg/kg/day oral dose of eplerenone. Blood pressure and urinary
by adrenalectomy attenuates renal injury in hypertensivealbumin were measured and kidneys were evaluated histologi-
rats independent of blood pressure reduction [3, 4].cally. Renal injury, inflammation, and fibrosis were assessed
Aldosterone/salt–induced hypertension has been usedby immunohistochemistry, in situ hybridization, and reverse
transcription-polymerase chain reaction (RT-PCR). for many years as a model of renal disease. The renal
Results. Aldosterone/salt induced severe hypertension com- damage that develops in this model is characterized his-
pared to controls (220  4 mm Hg vs. 131  4 mm Hg, P  topathologically by severe glomerular injury with vascu-
0.05), which was partially attenuated by eplerenone (179  lar fibrinoid necrosis and thrombotic microangiopathy
4 mm Hg, P  0.05). In aldosterone/salt treated rats, renal
[5], leading to renal fibrosis. Renal lesions are commonlyhistopathologic evaluation revealed severe vascular and glo-
accompanied by a marked inflammatory response, pri-merular sclerosis, fibrinoid necrosis and thrombosis, interstitial
marily involving mononuclear cells [5]. However, theleukocyte infiltration, and tubular damage and regeneration.
Aldosterone/salt increased circulating osteopontin (925.0  molecular mechanisms mediating the renal inflammatory
80.2 ng/mL vs. 53.6  6.3 ng/mL) and albuminuria (75.8  changes that occur in response to aldosterone/salt treat-
10.9 mg/24 hours vs. 13.2  3.0 mg/24 hours) compared to ment as well as cellular responses mediating the vascular
controls and increased expression of proinflammatory mole- and glomerular damage have not been studied in detail.cules. Treatment with eplerenone reduced systemic osteopon-
Recently, Luft [6] and Mervaala et al [7] have character-tin (58.3  4.2 ng/mL), albuminuria (41.5  7.2 mg/24 hours),
ized some of the inflammatory changes associated withand proinflammatory gene expression: osteopontin (OPN),
monocyte chemoattractant protein-1 (MCP-1), interleukin-6 the development of renal injury in models of angiotensin
(IL-6), and interleukin-1 (IL-1). II–induced hypertension. In these studies, angiotensin II
Conclusion. These findings indicate that aldosterone/salt– was proposed as the major factor responsible for mono-
induced renal injury and fibrosis has inflammatory components cyte recruitment and vascular inflammatory changes in
involving macrophage infiltration and cytokine up-regulation.
the kidney.Attenuation of renal damage and inflammation by eplerenone
In the present study, we evaluated the potential role ofsupports the protective effects of aldosterone blockade in hy-
aldosterone as a mediator of the cellular and molecularpertensive renal disease.
changes leading to renal inflammation and injury. Spe-
cifically, the effects of the selective aldosterone blocker,
Key words: aldosterone, renal, inflammation, eplerenone, cytokines. eplerenone [8], on renal inflammation and injury were
evaluated in the aldosterone/salt hypertensive rat model.Received for publication January 14, 2002
In addition, we studied the cellular localization of someand in revised form April 30, 2002, July 22, 2002, and November 8, 2002
Accepted for publication January 2, 2003 of the inflammatory cytokines involved. Our results indi-
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and fibrosis are associated with leukocyte infiltration and renone/g (1200 ppm) of chow resulting in an approxi-
mate dose of 100 mg/kg/day. This dose and route ofincreased expression of the proinflammatory cytokines
administration were determined to result in optimalosteopontin (OPN), monocyte chemoattractant protein-1
pharmacokinetic characteristics for effective in vivo inhi-(MCP-1), interleukin-1 beta (IL-1), and interleukin-6
bition of MR in the rat (abstract; Rocha R, Hypertension(IL-6), suggesting that inflammation is an important con-
38:479, 2001). Previous analytic work in our laboratoriestributor to renal damage in this model.
has demonstrated the stability of eplerenone in thisThe role of aldosterone in aldosterone/salt–induced
chow, as well as the homogeneity obtained after prepara-hypertension and end organ damage was evaluated using
tion. Briefly, pelleted eplerenone chow samples werethe novel, selective aldosterone blocker, eplerenone. We
ground into a fine powder, and in triplicate, 1 g samplesprovide evidence that aldosterone blockade attenuates
were placed into a 125 mL flask with 25 mL of samplerenal vascular injury and reduces cytokine expression
diluent [acetonitrile/H20 (60/40) (vol/vol)] and placedand subsequent inflammation. These data indicate for
onto a 250 rpm shaker for 30 minutes. Samples werethe first time that aldosterone, in addition to angiotensin
then filtered (0.45 m) and concentration tested usingII, plays a pivotal role in renal vascular damage in aldo-
chromatography. Percent recovery was calculated usingsterone/salt–induced hypertension in part by modulation
eplerenone LOQ standard and eplerenone chow sam-of inflammatory processes.
ples. Recovery was 100% (eplerenone chow ppm 
1320).
METHODS After recovery from surgery, animals were placed in
one of the following 28-day treatment protocols: (1)Animals
control (vehicle/normal chow/1% NaCl drinking water)The present study was conducted in male Sprague-
(N  7), (2) aldosterone infusion (aldosterone/normalDawley rats (250 to 270 g, N 24), obtained from Harlan
chow/1% NaCl drinking water) (N 9), and (3) aldoste-Sprague-Dawley Industries (Indianapolis, IN, USA). All
rone infusion  eplerenone (aldosterone/eplerenoneexperimental procedures received approval by the Insti-
chow/1% NaCl drinking water) (N  8).tutional Laboratory Animal Care and Use Committees
of Pharmacia Corporation. All animals were housed in Blood pressure analysis
a room lighted 12 hours per day at an ambient tempera-
Arterial blood pressure was monitored with a radio-ture of 22 1C. Animals were allowed 1 week to adjust
telemetry system using the DataquestA.R.TVersionafter arrival and had free access to rodent diet and tap
2.1-Gold software (Data Sciences, Inc., St. Paul, MN,
water until the initiation of the experiment. USA). Reported values represent the average of all data
points collected over a 24-hour period. Blood pressureSurgical procedure
was recorded for 10 seconds every 15 minutes throughout
Laparotomy was performed in rats anesthetized with the duration of the study. The 24-hour period used was
1% to 2% isoflurane (AErrane; Baxter, Inc., Deerfield, from 6:00 a.m. to 6:00 a.m.
IL, USA). Following left uninephrectomy, a radiotelem-
etry implant (Data Sciences, Inc., St. Paul, MN, USA) Sacrifice and tissue collection
was inserted in the abdominal aorta approximately 2 to Animals were anesthetized with pentobarbital (65 mg/kg
3 mm above the bifurcation of the iliac arteries for con- intraperitoneally), (Sigma Chemical Company) and ex-
tinuous monitoring of blood pressure. The abdominal sanguinated. Blood samples were centrifuged and plasma
wall was then sutured and postoperative pain was con- was collected and stored at 80C. Following exsangui-
trolled with a single dose of 0.1 to 0.5 mg/ kg subcutane- nation, the right kidney from each rat was removed, rinsed
ous injection of buphrenorphine (Rickett & Colman in cold saline, and blotted dry. Kidneys were immediately
Pharmaceuticals, Inc., Richmond, VA, USA). sectioned through the short axis into five slices. Three
slices were fixed in periodate-lysine-paraformaldehyde
Aldosterone and eplerenone treatment (9.2 mmol/L Na-m-periodate, 75 mmol/L lysine, 0.2 mol/L
At the time of surgery, an Alzet 2004 osmotic mini- paraformaldehyde) for 6 hours followed by 70% ethanol
pump (Alza Corp., Palo Alto, CA, USA) containing either for 18 hours and routinely processed and embedded in
vehicle (9% ethanol/87% propylene glycol/4% dH2O) paraffin. The remaining two sections were immediately
or 2.9 mg/mL d-aldosterone (Sigma Chemical Company, dissected on ice, separating medulla from cortex, and
St. Louis, MO, USA) was inserted subcutaneously be- immediately snap-frozen in liquid nitrogen. Frozen sam-
tween the shoulder blades. The dose of aldosterone ad- ples were stored at 80C for molecular analysis.
ministered was 0.75 g/hour.
Histopathologic analysisEplerenone was administered in the chow (Purina 5002
rodent diet  eplerenone; Research Diets, Inc., New Kidney sections (3 m) were stained with the periodic
acid-Schiff (PAS) method and with hematoxylin andBrunswick, NJ, USA) at a concentration of 1.2 mg eple-
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eosin and examined by light microscopy in a blinded sion (Kodak, Rochester, NY, USA) and exposed for 3
and 5 weeks at 4C prior to development. Developedfashion by a pathologist. The following histologic param-
eters were graded: glomerular injury, arterial injury, in- slides were counterstained with hematoxylin and eosin.
terstitial fibrosis, tubular dilation, protein casts, and in-
Plasma and urine assaysflammatory cell infiltrates. A semiquantitative grading
system (0 to 4) was utilized as follows: 0  no damage, Urinary albumin, plasma OPN, and plasma renin activ-
ity were assayed according to standard procedures.1  minimal damage with 1 or a few small foci, 2 
mild damage with small to moderately sized foci, 3  Briefly, albumin was determined using the Nephrat Al-
bumin enzyme-linked immunosorbent assay (ELISA) kitmoderate damage with frequent and moderately sized
foci, and 4  severe damage with extensive confluent (Exocell, Philadelphia, PA, USA). Rat OPN was deter-
mined using a rat OPN EIA kit (IBL Co., Gunma, Ja-foci affecting most of the kidney.
pan). Plasma renin activity was determined by standard
Immunohistochemistry radioimmunoassay (RIA) procedures for an estimation
of the primary product of renin activity, angiotensin ISections (5 m) were immunostained following stan-
dard procedures using primary antibodies for OPN (work- (NEN Life Science Products).
ing dilution 1:100, The University of Iowa, Iowa City,
RNA isolationIA, USA), ED1 (working dilution 1:500; Chemicon, Inc.,
Temlecula, CA, USA), CD3 (working dilution 1:1000; RNA was extracted from frozen renal cortex using
the Totally RNA Isolation Kit (Ambion, Inc., Austin,DAKO, Carpinteria, CA, USA) and vimentin (working di-
lution 1:100; Novocastra, Burlingame, CA, USA). Briefly, TX, USA) as previously described [9]. Tissues were
crushed, homogenized, and denatured according to man-sections were deparaffinized, rehydrated in ethanol, and
processed for antigen retrieval (Target Retrieval Solu- ufacturer’s instructions. RNA was further purified by
DNase digestion to remove genomic DNA and LiCl pre-tion, DAKO). Positive staining was detected using ap-
propriate biotin-labeled secondary antibodies, horserad- cipitation to remove carbohydrates. Briefly, 100 g of
RNA was incubated for 45 minutes at 37C with 1 unitish peroxidase-conjugated streptavidin (DAKO), and by
incubating the sections in diaminobenzidine (DAKO). of DNAse (Roche Diagnostics, Indianapolis, IN, USA)
and 10 units RNAse inhibitor (Applied Biosystems, Fos-Nonspecific isotype-matched immunoglobulin G (IgGs)
at similar concentrations were used as primary antibod- ter City, CA, USA) in a buffer containing 40 mmol/L
Tris pH 7.8, 6 mmol/L MgCl2, and 10 mmol/L CaCl2.ies for negative controls, and tissues known to express
these targets were used as positive controls. DNAse and buffer were removed using RNeasy (Qiagen,
Valencia, CA, USA), RNA was precipitated with 7.5
In situ hybridization mol/L LiCl/50 mmol/L ethylenediaminetetraacetic acid
(EDTA), and incubated overnight at20C. All samplesProbe templates for rat OPN, type III collagen, and
rat MCP-1 were generated by RT-PCR and labeled by were diluted and analyzed spectrophotometrically for
concentration and purity and stored at 80C.in vitro transcription with 33P-deoxyuridine triphosphate
(dUTP) to generate sense and antisense riboprobes (NEN
TaqMan quantitative RT-PCRLife Science Products, Boston, MA, USA). The follow-
ing primers were used: OPN (forward primer, 5	-TGG All primers and probes were designed using Primer
Express software supplied with the 7700 Sequence De-CAC ATT TGT CTT; reverse primer 3	-AGC CCA
TCC AGTC), MCP-1 (forward primer, 5	-CCA CTC tection System based on known rat sequences and syn-
thesized by Applied Biosystems (Foster City, CA, USA)ACC TGC TGC TAC TCA; reverse primer, 3	-ATC
ACA CTA AAC CTA CAC TAC G), type III collagen as previously described [10]. Standard curves were per-
formed to determine the efficiency of each primer/probe(forward primer, 5	-TGG CAC ATT TGT CTT; reverse
primer, 3	-CTG ACC TAC CCG A). Sections were de- set in the TaqMan reaction prior to the analysis of the
experimental samples. All target gene results were nor-paraffinized in xylene, rehydrated in graded ethanol solu-
tions, and fixed in 4% paraformaldehyde for 10 minutes malized to the housekeeping gene cyclophilin. Total, pu-
rified RNA (200 ng) was added to a RT-PCR reactionat 4C. Tissues were then digested with proteinase K (5
mg/mL; 10 minutes, 37C), washed, and prehybridized mix, which contained the following: 12.5 L of 2X One-
Step PCR Master Mix without uracil-N-glycosylase,in hybridization buffer [50% formamide, 2
 standard
sodium citrate (SSC), and 10% dextran sulfate] for 2 hours 0.625 L of a 40X MultiScribe and RNase Inhibitor Mix,
0.625 L of 20 mmol/L forward primer, 0.625 mL ofat 42C following dehydration in ethanol. Tissues were
hybridized overnight at 55C, washed in SSC buffer, and 20 mmol/L reverse primer, 0.5 mL of 5 mmol/L TaqMan
probe, and 0.125 mL of DNase/RNase-free water. Allslides were subsequently dehydrated in a graded series
of ethanol containing NH4OAc and dried in a vacuum samples were analyzed in duplicate. The following proto-
col was applied to all reactions: 30 minutes at 48C (re-desiccator. Slides were coated with photographic emul-
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Table 1. TaqMan primer-probe sets
Gene Forward Primer Reverse Primer Probe
Osteopontin (OPN) CCAGCACACAAGC TCAGTCCATAAG CAGTCGATGTCCCTGA
AGACGTT CCAAGCTATCAC CGGCCG
Monocyte chemoattractant protein (MCP-1) GCAGGTCTCTGTCA GGCTGAGACAG CCTGTTGTTCACAGTT
CGCTTCT CACGTGGAT GCTGCCTGTAGC
Interleukin-6 (IL-6) AGGAAGGCAGTGT CTTGGGTCCTC CAGCTACCTATGTCTT
CACTCATTGT ATCCTGGAA GCCCGTGGAGC
Interleukin-1 (IL-1) ATATGTTCTCAGGA TGCATCATCGCG TGAGAAAAGAGTTGT
GATCTTGGAA TTCATACAA TGCAATGGCAATTCTG
Cyclophilin AGAGAAATTTGAGG TTGTGTTTGGT AAGCATACAGGTCCTG
ATGAGAACTTCAT CCAGCATTTG GCATCTTGTCCAT
All oligonucleotides are written 5	 and 3	. Primers are unlabeled and all probes are labeled at the 5	 end with 6-carboxyfluorescein (6FAM) reporter dye and at
the 3	 end with 6-carboxy-N,N,N	,N	-tetramethylrhodamine (TAMRA) quencher dye.
verse transcription), 10 minutes at 95C (inactivation of
reverse transcriptase), 40 cycles of 15 seconds at 95C
and 1 minute at 60C (PCR). Data analysis was per-
formed using the Sequence Detection System software
from Applied Biosystems. Table 1 contains complete
primer and probe sequences for OPN, IL-1, IL-6,
MCP-1, and cyclophillin genes.
Statistical analysis
Data were analyzed using one-way analysis of variance
(ANOVA). Parametric analysis was performed for sys-
tolic blood pressure and biochemical assays data. In all
other cases, statistical analysis was performed on the
rank transforms of the raw data or ordinal data (nonpara- Fig. 1. Systolic blood pressure measured over time using radioteleme-
try in control, aldosterone/1% NaCl, and aldosterone/1% NaCl epler-metric analysis) to account for any inequality of variance.
enone rats. All rats were uninephrectomized and placed on 1% NaClThe alpha  0.05 level of significance was used for the for 28 days and received subcutaneous minipumps containing either
planned comparisons between the means. The Least Sig- vehicle or aldosterone (0.75 g/hour). Eplerenone was administered in
the diet at a dose of 100 mg/kg/day. Values represent mean  SEM.nificant Differences (LSD) method was used for planned
*P  0.05 vs. control; P  0.05 vs. aldosterone/1% NaCl.
comparisons between groups. Data were analyzed using
PROC GLM in the SAS statistical software package
(SAS PC, version 6.12, SAS Institute, Cary, NC, USA).
All data are reported as mean  standard error mean Physiologic and biochemical characteristics
(SEM). All physiologic and biochemical data are presented in
Table 2. Body weights were significantly lower in aldoste-
rone/salt–treated animals compared to controls. Eplere-RESULTS
none-treated animals maintained body weights similar
Blood pressure to control animals. Urinary albumin was markedly ele-
Systolic blood pressure did not increase in control ani- vated in aldosterone/salt–treated animals compared to
mals over 28 days (final measurement, 131  4 mm Hg) control animals and eplerenone significantly reduced al-
(Fig. 1). Aldosterone/salt treatment induced a progres- dosterone/salt–induced albuminuria. Plasma renin activ-
sive increase in blood pressure over time, resulting in ity (PRA) was low in all experimental groups (Table 2).
severe hypertension (final measurement, 220 4 mm Hg). Aldosterone infusion significantly elevated plasma OPN
Animals receiving eplerenone also developed a progres- levels (925  80.1 ng/mL vs. 53.6  6.3 ng/mL, P 
sive increase in blood pressure, although this increase 0.05) compared to controls, whereas eplerenone treated
was not as large as in the aldosterone/salt–treated ani- animals had plasma OPN levels that were similar to
controls (58.3  4.2 ng/mL vs. 53.6  6.3 ng/mL).mals (final measurement, 179  4 mm Hg).
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Table 2. Physiologic and biochemical characteristics
Aldosterone/
Aldosterone/ 1% NaCl 
Parameter Units Control 1% NaCl eplerenone
Systolic blood pressure mm Hg 1314 2204a 1794a,b
Body weight g 3804 2939a 3887b
Plasma renin activity ng/mL/hour 0.370.11 0.890.25a 0.060.03b
Plasma osteopontin ng/mL 53.66.3 925.080.2a 58.34.2b
Urinary albumin mg/24 hours 13.23.0 75.810.9a 41.57.2a,b
Eplerenone administered at 100 mg/kg/day. Values represent group mean  SEM.
a P  0.05 vs. control; b P  0.05 vs. aldosterone/1% NaCl
Table 3. Histopathological renal scores
Aldosterone/
Aldosterone/ 1% NaCl 
Parameter Units Control 1% NaCl eplerenone
Number affected glomeruli (0–4) 0.00.0 3.40.2a 1.50.3a,b
Number arteries affected (0–4) 0.00.0 3.70.3a 0.50.3a,b
Interstitial fibrosis (0–4) 0.20.2 2.80.3a 1.30.3a,b
Tubular dilation (0–4) 0.30.2 3.20.4a 1.30.2a,b
Protein casts (0–4) 0.30.2 3.10.4a 1.10.1a,b
Inflammatory cells (0–4) 0.30.2 2.30.2a 1.10.2a,b
Eplerenone administered at 100 mg/kg/day. Values represent group mean  SEM.
a P  0.05 vs. control; b P  0.05 vs. aldosterone/1% NaCl
Renal histopathology interstitium as well as areas of necrosis and degeneration,
while CD3-positive T cells were observed multifocallyMean histopathology kidney grades per group are pre-
in the interstitium (Fig. 2H). ED1- and CD3-positivesented in Table 3. Kidneys from control animals were
cells were less frequent in eplerenone-treated animalshistologically normal (Fig. 2A), while kidneys from aldo-
(Fig. 2 F and I). The degree of tubular damage and regen-sterone/salt–treated animals demonstrated severe glo-
eration was evaluated by vimentin immunohistochemis-merular and renal vascular injury (Fig. 2B). Renal vascu-
try. Vimentin-positive tubular epithelial cells were rarelylar damage consisted of severe degenerative changes in
found in control animals (Fig. 2J). In contrast, in aldoste-the arterioles and small arteries characterized by circum-
rone/salt–treated animals, many tubules were vimentinferential, transmural fibrinoid necrosis, thrombosis, myo-
positive (Fig. 2K), while the density of vimentin-positiveintimal proliferation, and adventitial fibrosis resulting in
tubules was markedly lower in the eplerenone-treatedthickening of the vessel walls. Glomerular changes con-
animals (Fig. 2L). The degree of interstitial fibrosis wassisted of expansion of glomerular tufts with fibrin deposi-
evaluated using a routine semiquantitative histopatho-tion, dilation, and thrombosis of glomerular capillaries,
logic examination. Additionally, type III collagen expres-and various degrees of mesangiolysis, hemorrhage, and
sion was visualized and localized by in situ hybridization.early glomerular sclerosis. Renal vascular and glomeru-
While rarely detected in both control and eplerenone-lar lesions were accompanied by inflammatory changes
treated animals (Fig. 2 M and O), type III collagen mRNAwith leukocyte infiltration and multifocal interstitial fi-
was easily detected in the cortex of aldosterone/1% NaClbrosis. Consistent with the high levels of albuminuria,
rats (Fig. 2N), indicating fibrosis. By immunohistochem-significant tubular dilation associated with large protein-
istry and in situ hybridization, OPN expression was lim-aceous casts was observed. In animals receiving eplere-
ited to scattered medullary tubules in control animals. Innone, lesions were markedly reduced compared to aldo-
contrast, in aldosterone/salt–treated animals, OPN ex-sterone/salt–treated animals (Fig. 2C).
pression was markedly up-regulated throughout the me-
Immunohistochemical and in situ dulla in both proximal and distal cortical tubules, with
hybridization analysis the most robust up-regulation affecting the damaged and
regenerative tubules (Fig. 3 A and B). Scattered myointi-Kidney sections of aldosterone/salt–treated animals
mal cells of arteries and infiltrating macrophages alsocontained frequent interstitial inflammatory cell infil-
expressed OPN. However, positive staining for OPN wastrates in contrast to those of control animals. These in-
only occasionally detected in injured glomeruli. Admin-flammatory cell infiltrates consisted primarily of ED1-
positive macrophages (Fig. 2E) infiltrating the cortical istration of eplerenone dramatically decreased the num-
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Fig. 2. Representative photomicrographs from kidneys of control (left column), aldosterone/1% NaCl (middle column), and aldosterone/1%Na
Cl  eplerenone (right column) rats after 28 days of treatment. Periodic acid-Schiff (PAS) staining. Kidneys from control rats appeared normal
(A), while kidneys from aldosterone/1% NaCl animals (B) displayed marked vascular and glomerular damage characterized by arterial fibrinoid
necrosis with segmental myointimal proliferation and adventitial fibrosis (black arrow), glomerular mesangiolysis with fibrinoid necrosis and
thrombosis (arrowhead), leukocyte infiltration, protein casts, and tubular dilation (white arrows). With eplerenone treatment (C ), injuries were
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Fig. 3. Representative photomicrographs of osteopontin (OPN) immunohistochemistry and in situ hybridization. OPN was detected in the medulla
(loop of Henle, distal nephrons) of control rats but only rarely in the cortex. Following aldosterone/1% NaCl treatment (A and B), OPN expression
was markedly up-regulated in the medulla and in both proximal and distal cortical tubules, with the most robust up-regulation affecting the
damaged and regenerative tubules (arrows). Scattered myointimal cells of arteries (arrowheads) and infiltrating macrophages also expressed OPN.
Aldosterone/1% NaCl rats treated with eplerenone exhibited only limited OPN staining (C and D). (A and C, 
200; B and D, 
200, bright-field
microscopy).
ber of cortical and medullary tubules expressing OPN, ular endothelial and epithelial cells (Fig. 4 A and B).
Administration of eplerenone markedly reduced MCP-1as well as the intensity of the signals observed by in situ
hybridization, indicating the marked overall reduction expression in the kidney, as MCP-1 mRNA could only
be detected in scattered interstitial macrophages (Fig. 4in renal OPN expression following eplerenone treatment
(Fig. 3 C and D). In control animals, MCP-1 mRNA could C and D).
not be detected by in situ hybridization. In contrast,
Renal gene expressionin aldosterone/salt–treated animals, MCP-1 mRNA was
detected multifocally in damaged and regenerative tu- Expression of proinflammatory marker genes was
quantitatively assessed to examine the potential molecu-bules, interstitial macrophages, scattered vascular smooth
muscle cells and arteriolar endothelial cells, and glomer- lar mediators of aldosterone/salt–induced renal damage.

markedly reduced (A to C, 
100). ED1 and CD3 immunostaining of control, aldosterone/1% NaCl and aldosterone/1% NaCl  eplerenone rats.
In contrast to those of control animals (D and G ), kidney sections of aldosterone/1% NaCl rats contained frequent ED1-positive macrophages
(E ) within the interstitium (arrow) and blood vessels (arrowhead), as well as CD3-positive T cells (H; arrow). ED1 and CD3 immunohistochemistry
demonstrated a lower number of infiltrating macrophages and T cells in the eplerenone-treated rats (F and I ) (D to I, 
100). Vimentin
immunohistochemistry. Vimentin-positive tubular epithelial cells were rarely found in control ( J ) and aldosterone/1% NaCl  eplerenone (L )
rats in contrast to aldosterone/1% NaCl rats, where many tubules were vimentin positive (K; arrows) (J to L, 
50). Type III collagen in situ
hybridization was used to demonstrate the early fibrosis in aldosterone/1% NaCl rats (N; arrows), while type III collagen mRNAs were rarely
detected in both control (M ) and aldosterone/1% NaCl  eplerenone (O) rats (M to O, 
50, dark-field microscopy).
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Fig. 4. Representative photomicrographs of monochemoattractant 1 (MCP-1) in situ hybridization in the kidneys of aldosterone/1% NaCl (A and B)
and aldosterone/1% NaCl  eplerenone (C and D ) rats. MCP-1 mRNA could rarely be detected in the kidneys of control and eplerenone-treated
rats. In contrast, in aldosterone/1% NaCl animals, MCP-1 mRNA was detected multifocally in damaged and regenerative tubules (arrows), as
well as in interstitial macrophages, scattered vascular smooth muscle cells, scattered arteriolar endothelial cells, and glomerular endothelial and
epithelial cells. (A and C, 
 200, bright-field microscopy; B and D, 
200, dark-field microscopy).
Renal expression levels of OPN, MCP-1, IL-1, and IL-6 renal injury, leukocyte infiltration and cytokine expres-
sion levels were all markedly attenuated by eplerenone,were significantly increased following 28 days of aldoste-
a selective aldosterone blocker, supporting the renopro-rone infusion compared to controls and this elevated
tective effects of MR antagonism in hypertensive ne-expression was significantly attenuated by eplerenone
phropathy. In the present study, the renal inflammatorytreatment (Fig. 5 A to D).
response and marked vascular and glomerular damage
induced by aldosterone/salt treatment are prominent. Al-
DISCUSSION though previous studies demonstrate the existence of
In this study, we investigated the renal cellular and mo- an inflammatory response prior to the development of
lecular changes associated with aldosterone/salt hyper- myocardial injury in the aldosterone/salt rat, in the ab-
tension in the rat. Aldosterone/salt treatment induced se- sence of a time-course evaluation, a causal relationship
vere hypertension and associated renal vascular injury, between inflammation and renal vascular damage cannot
glomerulosclerosis, tubular dilation and injury, and inter- be established in the current study [11].
stitial fibrosis. Our results indicate that aldosterone/salt– Historically, renal inflammation has been described
induced renal injury and fibrosis is associated with leu- as a feature of experimental hypertensive renal injury
kocyte infiltration and increased expression of various models. In the mineralocorticoid/salt hypertension model,
proinflammatory cytokines, including OPN, MCP-1, IL-1, original studies by Selye [12] described nephrosclerotic
and IL-6, suggesting that inflammation is an important lesions associated with proteinuria and inflammatory
vascular changes, which he described as “lesions of peri-component of renal damage in this model. In addition,
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reported the up-regulated expression of various pro-
inflammatory molecules [MCP-1, vascular endothelial
adhesion molecule, intracellular adhesion molecule, tu-
mor necrosis factor- (TNF-), IL-1, and OPN] in high
renin-driven hypertensive renal injury models where an-
giotensin II was proposed to be the primary mediator
of renal inflammation and injury [7, 16–19].
As a component of the extracellular matrix as well
as a circulating adhesion molecule, the chemoattractant
cytokine, OPN likely plays a role in the renal inflamma-
tory response following aldosterone/salt treatment by con-
tributing to macrophage recruitment and adhesion [20–22].
Renal OPN expression was primarily localized to injured
and regenerating tubules throughout the medulla and
cortex and was also present in infiltrating macrophages.
Elevated OPN expression and localization were associ-
ated with the severity of renal damage in aldosterone/
salt–treated animals. No significant OPN expression was
Fig. 5. Renal cortex mRNA levels of proinflammatory genes osteopon- found in glomeruli except for those in which marked
tin (OPN) (A ), monocyte chemoattractant protein-1 (MCP-1) (B ), injury and associated macrophage infiltration was pres-interleukin-1 (IL-1) (C ) and interleukin-6 (IL-6) (D ) from control,
ent. These findings are consistent with studies in ne-aldosterone/1% NaCl (Aldo) and aldosterone/1% NaCl  eplerenone
(Aldo  epl) rats after 28 days of treatment. Eplerenone was adminis- phropathy models where significant macrophage accu-
tered in the diet at a dose of 100 mg/kg/day. Values represent means  mulation and OPN expression also involved damaged
SEM. *P  0.05 vs. control; P  0.05 vs. aldosterone/1% NaCl.
tubules [15, 17]. They are also in agreement with previous
findings in the DOCA-salt hypertensive rat, which dem-
onstrated marked OPN expression in both damaged glo-
meruli and tubules [23]. In the present study, circulatingarteritis nodosa.” Subsequently, Heptinstall and Hill [5]
OPN levels were significantly elevated in plasma fromalso demonstrated inflammatory changes in kidneys of
aldosterone/salt–treated animals compared to control anddeoxycorticosterone acetate (DOCA)-salt hypertensive
eplerenone-treated animals. The same pattern of responserats. More recently, Beswick et al [13] demonstrated that
between plasma and renal OPN levels and the degree ofleukocyte infiltration in this model is associated with
renal damage in aldosterone/salt–treated animals suggestsreactive oxygen species accumulation and nuclear factor-
that OPN may represent a biomarker of renal damage in
kappa B (NF-B) activation [13]. The current study ex- aldosterone-driven renovascular disease.
tends these findings indicating that the cytokines OPN, In addition to serving as a potent chemoattractant,
MCP-1, IL-1, and IL-6 are significantly up-regulated Verstrepen et al [24] described a role for OPN in renal
in the kidney of aldosterone/salt hypertensive rats. In tubular regeneration in an acute nephrotoxicity model.
addition, we report the presence of a severe cellular in- In the present study, renal OPN staining paralleled stain-
flammatory response involving primarily monocyte/mac- ing for vimentin, which is commonly associated with
rophages, but also T-cell lymphocytes in the kidney of renal tubular regeneration [25–27]. This finding suggests
aldosterone/salt hypertensive rats. To our knowledge, a dual role for OPN in aldosterone/salt–induced renal
injury in which it functions both as a chemoattractantthis study provides the first description of aldosterone/
cytokine as well as a modulator of tubular remodelingsalt–induced renal proinflammatory cytokine expression
and regeneration.and elucidation of the role of aldosterone in this process.
Renal protection by eplerenone was accompanied byThe role of inflammatory cytokine activation in aldo-
a significant decrease in blood pressure (179  4 mm Hgsterone-induced hypertensive renal injury is not well un-
vs. 220  4 mm Hg) and this reduction may contributederstood. IL-6 and IL-1 were up-regulated following
to the attenuation of renal damage and inflammation.aldosterone infusion together with the chemotactic and
Even though eplerenone can produce end organ protec-
adhesive factors, MCP-1 and OPN. IL-6 has been shown tion in the absence of blood pressure reduction in other
to induce MCP-1 expression in human mesangial cells experimental models of hypertension, the aldosterone/
[14], while IL-1 is known to directly up-regulate OPN salt hypertension model does not allow this distinction
expression in renal epithelial cells [15]. However, from [6, 28]. Thus, a recognized limitation of the current study
the present study, it is not possible to understand fully the is the inability to discern the contribution of the blood
relationship between the different cytokines and their pressure dependent and independent mechanisms of or-
individual contributions to renovascular damage in aldo- gan protection. It should be noted that an additional
mechanism by which eplerenone reduces renal inflam-sterone/salt hypertensive rats. Previous studies have also
Blasi et al: Effect of eplerenone on renal vascular injury and inflammation1800
tive aldosterone receptor antagonist. Curr Opin Pharmacol 1:190–mation and injury may be related to the significant reduc-
196, 2001
tion in albuminuria. Indeed, excessive urinary protein 9. McCormick SP, Ng JK, Veniant M, et al: Transgenic mice that
overexpress mouse apolipoprotein B. Evidence that the DNA se-has been described as a potential mediator of renal pro-
quences controlling intestinal expression of the apolipoprotein Binflammatory gene expression [15, 29, 30]. gene are distant from the structural gene. J Biol Chem 271:11963–
11970, 1996
10. Tada M, Omata M, Kawai S, et al: Detection of ras gene mutations
in pancreatic juice and peripheral blood of patients with pancreaticCONCLUSION
adenocarcinoma. Cancer Res 53:2472–2474, 1993
Animals treated with the mineralocorticoid, aldoste- 11. Rocha R, Rudolph AE, Frierdich GE, et al: Aldosterone induces
a vascular inflammatory phenotype in the rat heart. Am J Physiolrone, in the presence of salt developed severe hyperten-
Heart Circulatory Physiol 283:H1802–H1810, 2002sion, renal inflammation and injury, albuminuria, and 12. Selye H: The general adaptation syndrome and the diseases of
elevated expression of the proinflammatory molecules adaptation. J Clin Endocrinol 6:117–230, 1946
13. Beswick RA, Zhang H, Marable D, et al: Long-term antioxidantOPN, MCP-1, IL-1 and IL-6. Aldosterone-induced re-
administration attenuates mineralocorticoid hypertension and re-
nal injury, inflammation, and fibrosis were effectively nal inflammatory response. Hypertension 37:781–786, 2001
14. Coletta I, Soldo L, Polentarutti N, et al: Selective inductionattenuated by the selective aldosterone blocker, eplere-
of MCP-1 in human messangial cells by IL-6/sIL-6R complex. Expnone. We postulate that aldosterone may, at least in part,
Nephrol 8:37–43, 2000
contribute to renal inflammation and injury via modula- 15. Yu XQ, Fan JM, Nikolic-Paterson DJ, et al: IL-1 up-regulates
osteopontin expression in experimental crescentric glomerulo-tion of cytokine expression, which promotes inflammatory
nephritis in the rat. Am J Pathol 154:833–841, 1999cell infiltration and albuminuria in hypertension-driven 16. Taal MW, Zandi-Nejad K, Weening B, et al: Proinflammatory
gene expression and macrophage recruitment in the rat remnantrenal injury. Thus, the establishment of aldosterone as
kidney. Kidney Int 58:1664–1676, 2000a pivotal contributor to renal hypertensive disease has
17. Yu XQ, Wu LL, Huang XR, et al: Osteopontin expression in
become paramount to understanding the etiology of this progressive renal injury in remnant kidney: Role of angiotensin
II. Kidney Int 58:1469–1480, 2000disease state.
18. Hilgers KF, Hartner A, Porst M, et al: Monocyte chemoattrac-
tant protein-1 and macrophage infiltration in hypertensive kidney
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